CpdA's selective GR actions and to a lesser extent its antagonistic AR actions also contribute to the compound's ability to inhibit bladder cancer cell proliferation, colony formation, cell migration and invasion, and to increase cell cycle arrest and apoptosis [41]. Here, NR3C1 is linked to urinary bladder carcinoma.